DrugPatentWatch Database Preview
Drugs in Development Information for Huperzine A
What is the drug development status for Huperzine A?
Huperzine A is an investigational drug.
There have been 11 clinical trials for Huperzine A.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Alzheimer Disease, Cognition Disorders, and Seizures. The leading clinical trial sponsors are Biscayne Neurotherapeutics, Inc., Baylor College of Medicine, and Spaulding Rehabilitation Hospital.
Summary for Huperzine A
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 831 |
| WIPO Patent Applications | 522 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 2 (2009-12-01) |
| Vendors | 91 |
Recent Clinical Trials for Huperzine A
| Title | Sponsor | Phase |
|---|---|---|
| BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | Biscayne Neurotherapeutics Australia Pty, Ltd. | Phase 1/Phase 2 |
| BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | Biscayne Neurotherapeutics, Inc. | Phase 1/Phase 2 |
| Bioavailability, Safety, and Tolerability of BIS-001 ER | Melbourne Health | Phase 1 |
Clinical Trial Summary for Huperzine A
Top disease conditions for Huperzine A
Top clinical trial sponsors for Huperzine A
US Patents for Huperzine A
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
